Skip to content

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).

Double-Blind, Randomized, Placebo-Controlled, Single- Center, Dose Optimization Study Evaluating Efficacy and Safety of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults Aged 18-65 Years With a Diagnosis of ADHD

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02141113
Acronym
ADINT2012
Enrollment
26
Registered
2014-05-19
Start date
2012-11-30
Completion date
2014-11-30
Last updated
2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Attention-Deficit Hyperactivity Disorder

Brief summary

This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride. The hypothesis is that this medication could be used in adults with Attention Deficit/Hyperactivity Disorder who have not received satisfactory results with their current stimulant ADHD medication. The study drug is investigational for use in adults. Investigational means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in adults.

Detailed description

The purpose of this study is to determine whether guanfacine hydrochloride used as an adjunct therapy (to subjects' current stimulant medication) would bring about a statistically significant improvement in AD/HD symptoms.

Interventions

DRUGGuanfacine Hydrochloride

1. mg Guanfacine Hydrochloride (orally) 2. mg Guanfacine Hydrochloride (orally) 3. mg Guanfacine Hydrochloride (orally) 4. mg Guanfacine Hydrochloride (orally) 5. mg Guanfacine Hydrochloride (orally) 6. mg Guanfacine Hydrochloride (orally)

OTHERPlacebo

Placebo of matching mg

Sponsors

Shire
CollaboratorINDUSTRY
Rochester Center for Behavioral Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Male and females (non pregnant) ages 18-65 * Current diagnosis of ADHD and have met the DSM-IV-TR criteria for ADHD * Currently taking an adequate dose stimulant to treat their ADHD (with a sub-optimal response). A suboptimal response is determined by a baseline score of 28 or greater on the ADHD-RS or a CGI score of 4 or greater. * Subjects must be of normal intelligence * English speaking * Able to swallow pills.

Exclusion criteria

* Non pregnant or lactating females * Severe Axis I and Axis II disorders * Suicidal * Tourette's * Heart disease or any other serious chronic or acute unstable medical conditions/illnesses that would compromise participation or likely lead to hospitalization during the duration of the study. * A known history or presence of cardiovascular, hepatic, renal, respiratory, or hematologic abnormalities, narrow angle glaucoma, or any other unstable medical or psychiatric conditions (as judged by the primary investigator) * A current or recent history (within the past 6 months) of suspected substance abuse and/or drug dependence as defined by DSM-IV-TR criteria * Healthy weight (not under or over as judged by investigator) * No immediate family member of the investigator or research staff No involvement in a research study in the last 30 days.

Design outcomes

Primary

MeasureTime frameDescription
ADHD-RS Change From Baseline to Endpoint0 weeks, 8 weeksThe ADHD-RS is an 18-item scale based on DSM-IV criteria for ADHD. Each item is rated using a likert scale from 0 (none) to 3 (severe), with a total score range of 0-54, with higher scores indicating more symptoms/severity. In this study, we compared the mean change in ADHD-RS total score from baseline to endpoint of the study.

Secondary

MeasureTime frameDescription
The Clinical Global Impression (Severity)0 weeks, 8 weeksThe Clinical Global Impression- Severity (CGI-S) is a clinician-assessed likert scale used to determine the severity of a patient's presenting symptoms. The scale evaluates a subject's illness from 1 (normal, not at all ill) to 7 (extremely ill). The results reported below indicate the magnitude of change in terms of mean points on a scale for each study condition (IMP or Placebo).
The Clinical Global Impression- Improvement (CGI-I)8 weeksThe Clinical Global Impression-Improvement (CGI-I) is a clinician-assessed likert scale measuring change in presenting symptoms from previous visit. The CGI-I is a 7-item scale with with 1 indicating that the subject has very much improved and 7 indicating that the subject has become very much worse.

Other

MeasureTime frameDescription
Hamilton Depression Rating Scale (HAM-D) Change From Baseline to Endpoint0 weeks, 8 weeksThe HAM-D is a clinician administered multiple item scale used to provide an indication of depression symptom severity. It is designed for adults. Each item on the questionnaire is scored on a 3 or 5 point scale. The HAM-D is comprised of 21 items, however, the total score is based on the sum of the scores from the first 17 items. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Thus the possible total score range is 0 (minimum) to 40 (maximum) with a higher score indicating greater severity of depression. Accordingly, a low HAM-D score would indicate a better outcome. Mean change scores from baseline (visit 0) to endpoint (visit 8) are presented below.
Fatigue Symptoms Inventory (FSI) Change From Baseline to Endpoint0 weeks, 8 weeksThe FSI is a 14-item self-report measure designed to assess the severity, frequency, and daily pattern of fatigue as well as its perceived interference with quality of life. Severity is measured on separate 11-point scales (0=not at all fatigued; 10=as fatigued as I could be) that assess most, least, and average fatigue since last visit, as well as current fatigue. The minimum score would be 0, maximum score would be 140. Scores below reflect mean improvement in FSI score from baseline (visit 0) to endpoint (visit 8). The FSI was used to measure safety and tolerability of study drug.
The Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to Endpoint0 weeks, 8 weeksThe Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The individual self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Total score range is from 0 to 21. The mean improvement from baseline (visit 0) to endpoint (visit 8) are presented below. PSQI was used to assess safety and tolerability of study drug.
Hamilton Anxiety Inventory Change From Baseline to Endpoint0 weeks, 8 weeksThe Hamilton Anxiety Scale is a 14-items clinician-rated scale designed to measure anxiety severity. Each of the 14 items is scored from 0 (symptom not persent) to 4 (severe symptom). The total range is 0-56. A total score of less than 17 indicates mild severity, 18-24 indicates mild to moderate severity, and a score of 25-30 indicates moderate to severe symptoms. In this study, we compared the mean change in the Hamilton Anxiety scale from baseline to week 8 between guanfacine hyrdochloride and placebo-treated patients to assess safety and tolerability of study drug.
Arizona Sexual Experiences Scale (ASEX) Change From Baseline to Endpoint0 weeks, 8 weeksThe Arizona Sexual Experiences Scale (ASEX) is both a self-administered or clinician-administered questionnaire. It is a user-friendly 5-item rating scale. The ASEX utilizes short, easy to understand, and less intrusive questions that explores the follwoing aspects of sexuality: 1. sex drive 2. arousal 3a. penile erection 3b. vaginal lubrication 4\. ability to reach orgasm 5. satisfaction from orgasm Scores can range from a minimum of 6 (indicating minimal problems with sexual functioning) to 36 (indicating maximum problems with sexual functioning). Mean change from baseline (visit 0) to endpoint (visit 8) are presented below. The ASEX was used to assess safety and tolerability of drug from baseline to endpoint

Countries

United States

Participant flow

Recruitment details

Study site began recruiting for the trial in November 2012 and the last subject completed the final visit on 3/7/14. Recruitment was done from within the Rochester Center for Behavioral Medicine (a private mental health practice), as well as community outreach.

Pre-assignment details

All participants were on a stable dose (as determined by the investigator) of a stimulant medication.

Participants by arm

ArmCount
Guanfacine Hydrocholride
1. mg Guanfacine Hydrochloride (orally, QD) 2. mg Guanfacine Hydrochloride (orally, QD) 3. mg Guanfacine Hydrochloride (orally, QD) 4. mg Guanfacine Hydrochloride (orally, QD) 5. mg Guanfacine Hydrochloride (orally, QD) 6. mg Guanfacine Hydrochloride (orally, QD) Guanfacine Hydrocholride: 1mg Guanfacine Hydrochloride (orally) 2mg Guanfacine Hydrochloride (orally) 3mg Guanfacine Hydrochloride (orally) 4mg Guanfacine Hydrochloride (orally) 5mg Guanfacine Hydrochloride (orally) 6mg Guanfacine Hydrochloride (orally)
13
Sugar Pill Guanfacine Hydrocholride
1. mg Guanfacine Hydrochloride (orally, QD) 2. mg Guanfacine Hydrochloride (orally, QD) 3. mg Guanfacine Hydrochloride (orally, QD) 4. mg Guanfacine Hydrochloride (orally, QD) 5. mg Guanfacine Hydrochloride (orally, QD) 6. mg Guanfacine Hydrochloride (orally, QD) Guanfacine Hydrocholride: 1mg Guanfacine Hydrochloride (orally) 2mg Guanfacine Hydrochloride (orally) 3mg Guanfacine Hydrochloride (orally) 4mg Guanfacine Hydrochloride (orally) 5mg Guanfacine Hydrochloride (orally) 6mg Guanfacine Hydrochloride (orally)
13
Total26

Baseline characteristics

CharacteristicGuanfacine HydrocholrideSugar Pill Guanfacine HydrocholrideTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
13 Participants13 Participants26 Participants
Region of Enrollment
United States
13 participants13 participants26 participants
Sex: Female, Male
Female
7 Participants5 Participants12 Participants
Sex: Female, Male
Male
6 Participants8 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 130 / 13
serious
Total, serious adverse events
0 / 130 / 13

Outcome results

Primary

ADHD-RS Change From Baseline to Endpoint

The ADHD-RS is an 18-item scale based on DSM-IV criteria for ADHD. Each item is rated using a likert scale from 0 (none) to 3 (severe), with a total score range of 0-54, with higher scores indicating more symptoms/severity. In this study, we compared the mean change in ADHD-RS total score from baseline to endpoint of the study.

Time frame: 0 weeks, 8 weeks

Population: All participants were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
TreatmentADHD-RS Change From Baseline to Endpoint11.85 units on a scaleStandard Deviation 7.63
Control GroupADHD-RS Change From Baseline to Endpoint10.92 units on a scaleStandard Deviation 8.9
Comparison: These scores were calculated by subtracting participants' endpoint scores from their initial baseline scores. These changed scores show the total change in ADHD symptoms over the course of the trial. Higher values indiicate improved functioning at the end of the trial compared to the beginning.p-value: 0.779ANOVA
Secondary

The Clinical Global Impression- Improvement (CGI-I)

The Clinical Global Impression-Improvement (CGI-I) is a clinician-assessed likert scale measuring change in presenting symptoms from previous visit. The CGI-I is a 7-item scale with with 1 indicating that the subject has very much improved and 7 indicating that the subject has become very much worse.

Time frame: 8 weeks

Population: Participants

ArmMeasureValue (MEAN)Dispersion
TreatmentThe Clinical Global Impression- Improvement (CGI-I)2.77 units on a scaleStandard Deviation 1.01
Control GroupThe Clinical Global Impression- Improvement (CGI-I)2.92 units on a scaleStandard Deviation 1.04
p-value: 0.705ANOVA
Secondary

The Clinical Global Impression (Severity)

The Clinical Global Impression- Severity (CGI-S) is a clinician-assessed likert scale used to determine the severity of a patient's presenting symptoms. The scale evaluates a subject's illness from 1 (normal, not at all ill) to 7 (extremely ill). The results reported below indicate the magnitude of change in terms of mean points on a scale for each study condition (IMP or Placebo).

Time frame: 0 weeks, 8 weeks

Population: Participants

ArmMeasureValue (MEAN)
TreatmentThe Clinical Global Impression (Severity).85 units on a scale
Control GroupThe Clinical Global Impression (Severity)1.0 units on a scale
p-value: 0.834ANOVA
Other Pre-specified

Arizona Sexual Experiences Scale (ASEX) Change From Baseline to Endpoint

The Arizona Sexual Experiences Scale (ASEX) is both a self-administered or clinician-administered questionnaire. It is a user-friendly 5-item rating scale. The ASEX utilizes short, easy to understand, and less intrusive questions that explores the follwoing aspects of sexuality: 1. sex drive 2. arousal 3a. penile erection 3b. vaginal lubrication 4\. ability to reach orgasm 5. satisfaction from orgasm Scores can range from a minimum of 6 (indicating minimal problems with sexual functioning) to 36 (indicating maximum problems with sexual functioning). Mean change from baseline (visit 0) to endpoint (visit 8) are presented below. The ASEX was used to assess safety and tolerability of drug from baseline to endpoint

Time frame: 0 weeks, 8 weeks

Population: All participants were included in the analysis.

ArmMeasureValue (MEAN)
TreatmentArizona Sexual Experiences Scale (ASEX) Change From Baseline to Endpoint-.77 units on a scale
Control GroupArizona Sexual Experiences Scale (ASEX) Change From Baseline to Endpoint1.31 units on a scale
p-value: 0.212ANOVA
Other Pre-specified

Fatigue Symptoms Inventory (FSI) Change From Baseline to Endpoint

The FSI is a 14-item self-report measure designed to assess the severity, frequency, and daily pattern of fatigue as well as its perceived interference with quality of life. Severity is measured on separate 11-point scales (0=not at all fatigued; 10=as fatigued as I could be) that assess most, least, and average fatigue since last visit, as well as current fatigue. The minimum score would be 0, maximum score would be 140. Scores below reflect mean improvement in FSI score from baseline (visit 0) to endpoint (visit 8). The FSI was used to measure safety and tolerability of study drug.

Time frame: 0 weeks, 8 weeks

Population: Participants

ArmMeasureValue (MEAN)
TreatmentFatigue Symptoms Inventory (FSI) Change From Baseline to Endpoint0.69 units on a scale
Control GroupFatigue Symptoms Inventory (FSI) Change From Baseline to Endpoint5.77 units on a scale
p-value: 0.322ANOVA
Other Pre-specified

Hamilton Anxiety Inventory Change From Baseline to Endpoint

The Hamilton Anxiety Scale is a 14-items clinician-rated scale designed to measure anxiety severity. Each of the 14 items is scored from 0 (symptom not persent) to 4 (severe symptom). The total range is 0-56. A total score of less than 17 indicates mild severity, 18-24 indicates mild to moderate severity, and a score of 25-30 indicates moderate to severe symptoms. In this study, we compared the mean change in the Hamilton Anxiety scale from baseline to week 8 between guanfacine hyrdochloride and placebo-treated patients to assess safety and tolerability of study drug.

Time frame: 0 weeks, 8 weeks

Population: Participants

ArmMeasureValue (MEAN)
TreatmentHamilton Anxiety Inventory Change From Baseline to Endpoint3.62 units on a scale
Control GroupHamilton Anxiety Inventory Change From Baseline to Endpoint4.46 units on a scale
p-value: 0.043ANOVA
Other Pre-specified

Hamilton Depression Rating Scale (HAM-D) Change From Baseline to Endpoint

The HAM-D is a clinician administered multiple item scale used to provide an indication of depression symptom severity. It is designed for adults. Each item on the questionnaire is scored on a 3 or 5 point scale. The HAM-D is comprised of 21 items, however, the total score is based on the sum of the scores from the first 17 items. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Thus the possible total score range is 0 (minimum) to 40 (maximum) with a higher score indicating greater severity of depression. Accordingly, a low HAM-D score would indicate a better outcome. Mean change scores from baseline (visit 0) to endpoint (visit 8) are presented below.

Time frame: 0 weeks, 8 weeks

ArmMeasureValue (MEAN)
TreatmentHamilton Depression Rating Scale (HAM-D) Change From Baseline to Endpoint3.31 units on a scale
Control GroupHamilton Depression Rating Scale (HAM-D) Change From Baseline to Endpoint4.23 units on a scale
Other Pre-specified

The Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to Endpoint

The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The individual self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Total score range is from 0 to 21. The mean improvement from baseline (visit 0) to endpoint (visit 8) are presented below. PSQI was used to assess safety and tolerability of study drug.

Time frame: 0 weeks, 8 weeks

ArmMeasureValue (MEAN)
TreatmentThe Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to Endpoint2.69 units on a scale
Control GroupThe Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to Endpoint2.08 units on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026